Trends in cognitive dysfunction following surgery for intracranial tumors

Manju Dhandapani, Sandhya Gupta¹, Manju Mohanty², Sunil Kumar Gupta³,
Sivashanmugam Dhandapani²

Neuronursing Division, National Institute of Nursing Education, Post Graduate Institute of Medical Education and Research, ¹Department of Neurosurgery, Post Graduate Institute of Medical Education and Research, Chandigarh, ²Psychiatric Nursing Division, College of Nursing, All India Institute of Medical Sciences, New Delhi, India

E-mail: Manju Dhandapani - manjuseban@gmail.com; Sandhya Gupta - drsandhya407@gmail.com; Manju Mohanty - manjumohanty2011@gmail.com; Sunil Kumar Gupta - drguptasunil@gmail.com; *Sivashanmugam Dhandapani - ssdhandapani.neurosurg@gmail.com

*Corresponding author

Received: 08 September 15  Accepted: 20 October 15  Published: 22 March 16

Abstract

Background: This study was conducted to prospectively assess the cognitive function of patients with intracranial tumors.

Methods: The cognitive status of patients with intracranial tumors were prospectively studied before surgery, and later at 1 and 6 months following surgery, on purposive sampling, using validated post graduate institute (PGI) battery for brain dysfunction (score 0–30) with a higher dysfunction rating score indicating poor cognitive status.

Results: Out of 23 patients enrolled, 20 could complete the study. They had substantial cognitive dysfunction before surgery (score 17.1 ± 9.4). Though there was no significant improvement (16.9 ± 9.0) at 1 month, the score improved significantly (10.3 ± 9.2) at 6 months following surgery (P = 0.008). The improvement was relatively subdued in intra-axial, malignant, and radiated tumors. Overall, there was a significant improvement in mental balance (P = 0.048), verbal retention of dissimilar pairs (P = 0.01), and recognition (P = 0.01), while dysfunction persisted in the domains of memory, verbal retention to similar pairs, and visual retention.

Conclusion: Patients with intracranial tumors have substantial cognitive dysfunction, which tend to show significant improvement beyond 6 months following surgery, especially among tumors, which were extra-axial, benign, and nonirradiated.

Key Words: Cognitive dysfunction, intracranial tumor, memory scales, surgery

INTRODUCTION

Intracranial tumors are one of the common causes of mortality and morbidity worldwide.[1,2,5,16,21] About 60–90% patients with intracranial tumors face cognitive impairments along with some emotional and behavioral changes.[1,3,5] Cognitive function, defined as the processes by which sensory input is elaborated, transformed, reduced, stored, recovered, and used,[27] is known to be altered in patients with intracranial tumors, encompassing memory deficits, confusion, inefficiency in executive functioning, poor attention span or concentration, organizational ability, poor arithmetic or language skills, lack of mental balance, inability to coordinate various motor activities, inability to learn or process new information, etc.[1,4,12,35]
Cognitive dysfunction in these patients can impair the intellectual functions, activities of daily living (ADL), interpersonal relationships, and education and profession of the patients. It may prevent them from fulfilling their familial, professional, and social obligations thus can lead to poor quality of life (QoL) not only in patients, but also in caregivers. The importance of identifying and managing the cognitive dysfunction is growing as the survival length and survival rate of these patients are increasing due to innovations in the treatment modalities.

The factors leading to cognitive deficits include paraneoplastic effects such as duration and location of the tumor, brain edema and associated neuroinflammation, and the impact of treatment modalities like surgery, chemotherapy, radiotherapy, or ventriculo-peritoneal shunt. It is reported that loss of white matter or failure of white matter to develop appropriate for the age can account for cognitive deficits. Cognitive dysfunction is reported in patients with intracranial tumors irrespective of the treatment modality they have undergone.

There is lack of evidence on the domains, magnitude, and duration of cognitive dysfunction present in patients with intracranial tumors. Cognitive deficits of these patients are neither monitored nor managed during the follow-up visits. Knowing the trend in cognitive dysfunction is necessary to develop protocols and tools for assessing cognitive function. Identifying the magnitude and type of cognitive dysfunction, may aid in various cognitive behavioral therapies to improve the QoL of patients and caregivers. Appropriate interventions can be developed based on the specific cognitive impairment of the patients. However, there is a paucity of studies on trends in cognitive dysfunction with respect to the treatment provided. With this in mind, this study was undertaken to assess the cognitive function of the patients with intracranial tumors before surgery, later at 1 month and 6 months following surgery.

**MATERIALS AND METHODS**

A longitudinal study was done to assess the cognitive changes in patients with intracranial tumors. Using purposive sampling, 23 newly diagnosed conscious intracranial tumor patients who were availing treatment from a Tertiary Care Center at Chandigarh and consented to the study were enrolled. Ethical clearance was obtained from the Institute Ethics Committee, and written consent was taken from all study subjects and guardians. All patients who underwent surgical management with or without radiotherapy or chemotherapy were followed up for cognitive assessment. Cognitive status was assessed before surgery, later at 1 month and 6 months following surgery.

Cognitive changes of patients were assessed using PGI battery for brain dysfunction (BBD) which assesses various domains of cognitive functions. For this study, patients were assessed for 10 domains remote memory, recent memory, mental balance, attention and concentration, delayed recall, immediate recall, verbal retention to similar and dissimilar pairs, visual retention, and recognition. PGI BBD is a valid and comprehensive tool with a test-retest reliability of up to 0.85 and split half reliability of 0.9.

The raw score of each domain was made into a converted score according to the educational level of the patients. The total dysfunction score was calculated by adding the dysfunction scores of all domains and higher the dysfunction rating score poorer the cognitive status. The total maximum possible score is 30 (3 in each domain).

SPSS 21 (IBM, New York, USA) was utilized for descriptive and inferential statistics. Repeated measures ANOVA was used to compare the dysfunction score at different assessment.

**RESULTS**

Out of 23 patients with intracranial tumors enrolled, 20 patients were followed up as 2 patients died, and 1 patient was lost to follow-up. As per the sociodemographic data of patients shown in Table 1, the mean age of the patients was 46.1 ± 10.1 years with a range of 29–70 years. Gender difference in patients was not much evident as 52% were male, and 48% were female. The majority of the patients (91%) were married. Furthermore, 48% of them were illiterate, and the employed patients accounted for 30%.

| Variables                   | n (%)       |
|-----------------------------|-------------|
| Age (years)                 |             |
| Mean±SD                     | 46.13±10.09 |
| Range                       | 29-70       |
| Gender                      |             |
| Female                      | 11 (48)     |
| Male                        | 12 (52)     |
| Education                   |             |
| Illiterate and primary      | 11 (48)     |
| Elementary to senior secondary | 8 (35)   |
| Graduate and above          | 4 (17)      |
| Marital status              |             |
| Married                     | 21 (91)     |
| Unmarried                   | 2 (9)       |
| Occupation                  |             |
| Unemployed                  | 15 (65)     |
| Employed                    | 7 (30)      |
| Student                     | 1 (4)       |

SD: Standard deviation
Table 2 reveals the clinical profile of the patients. It was found that 87% of the patients had supratentorial tumors and in 52% of the patients tumor was located on the left side of the brain. Illness onset was <1 month in 61% of the patients. Radiotherapy and chemotherapy, which was started after 2–3 weeks of surgery, were given to 30% and 13% of the patients, respectively. At 1 month assessment of cognitive function, they were on radiotherapy or chemotherapy, but none was receiving the same at 6 months.

**Cognitive changes in patients**

The cognitive function of the patients was significantly affected as the cognitive dysfunction score was 17.1 ± 9.4 out of 30 before any definite treatment (higher the score higher the dysfunction). There was an only mild nonsignificant improvement in the dysfunction rating score (16.91 ± 9.0) at 1 month of follow-up. There was a significant improvement only in recognition ($P = 0.04$).

There was a significant improvement in cognitive function at 6 months with the dysfunction rating score decreasing from 17.1 ± 9.4 to 10.3 ± 9.2 ($P = 0.01$) [Figure 1]. Among the domains of cognitive function, there was significant improvement at 6 months in mental balance ($P = 0.048$), verbal retention of dissimilar pairs ($P = 0.01$), and recognition ($P = 0.01$) [Table 3]. While other domains had shown trends toward improvement, recent memory, immediate recall, verbal retention to similar pairs, and visual retention did not change much.

As shown in Figures 2 and 3, cognitive dysfunction score was higher at all points of assessment in patients with intra-axial tumors and malignant tumors as compared to others. Patients who underwent radiotherapy were also found to have consistently higher dysfunction score [Figure 4], compared to those who did not receive radiotherapy. While even patients with infratentorial tumors had some cognitive dysfunction, which remained static, higher dysfunction score in patients with supratentorial tumors showed improvement with treatment [Figure 5].

![Figure 1: Cognitive dysfunction score of the patients ($P = 0.008$)](image)

### Table 2: Clinical profile of the patients ($n=23$)

| Variables                     | $n$ (%) |
|-------------------------------|---------|
| Tumor location                |         |
| Supratentorial                | 20 (87) |
| Infratentorial                | 3 (13)  |
| Tumor side                    |         |
| Right                         | 7 (30)  |
| Left                          | 12 (52) |
| Middle                        | 4 (18)  |
| Duration of illness at first visit |     |
| <1 month                      | 14 (61) |
| >1 month                      | 9 (39)  |
| Radiotherapy received         | 7 (30)  |
| Chemotherapy received         | 3 (13)  |

### Table 3: Domain-specific cognitive dysfunction score of the patients

| Cognitive function                   | Dysfunction rating score | $P$       |
|-------------------------------------|--------------------------|-----------|
|                                     | First visit   | 1 month   | 6 months | First visit versus 1 month | First visit versus 6 months |
| Remote memory                       | 1.2±1.28      | 1.14±1.39 | 0.85±1.38 | 1                       | 0.25                        |
| Recent memory                       | 0.8±1.15      | 0.33±0.85 | 0.5±1.1   | 0.14                    | 0.37                        |
| Mental balance                      | 2.15±1.31     | 2.05±1.24 | 1.35±1.46 | 0.6                     | 0.048*                      |
| Attention and concentration         | 2±1.38        | 2.1±1.14  | 1.6±1.54  | 0.8                     | 0.24                        |
| Delayed recall                      | 2.1±1.29      | 2.24±1.04 | 1.85±1.46 | 0.65                    | 0.41                        |
|Immediate recall                    | 0.95±1.36     | 1.33±1.46 | 0.95±1.39 | 0.41                    | 1                           |
| Verbal retention to similar pairs   | 1.8±1.28      | 2.05±1.12 | 1.65±1.46 | 0.26                    | 0.64                        |
| Verbal retention to dissimilar pairs| 2.6±0.94      | 2.29±1.19 | 1.8±1.32  | 0.22                    | 0.009*                      |
|Visual retention                     | 1.9±1.44      | 2.2±1.29  | 1.75±1.51 | 0.39                    | 0.659                       |
|Recognition                          | 1.6±1.39      | 1.19±1.44 | 0.7±1.3   | 0.038*                  | 0.014*                      |
|Total dysfunction rating score       | 17.1±9.36     | 16.91±8.98| 10.3±9.24 | 0.71                    | 0.008*                      |

*P<0.05
DISCUSSION

Cognitive dysfunction in patients with intracranial tumors is well evident in literature. However, there is paucity on a prospective analysis of cognitive dysfunction in these patients with respect to surgery. This study focused on trends in cognitive function from before surgery until 6 months after surgery.

There are many domains of cognitive function. There is no conclusive evidence on the particular domain being affected due to the difference in the cognitive tools used in various studies. In this study, most affected by all domains on first assessment was verbal retention to dissimilar pairs, an indicator of new learning. Other domains highly affected were a mental balance, attention, concentration, and delayed recall. The domains least affected were a recent memory and immediate recall. Cognitive deficits reported in literature include deficits in working memory, cognitive control, cognitive processing speed, visual searching, planning foresight, general attention, executive function, language, concentration performance intelligent quotient, verbal intelligent quotient, and visuoconstruction.

Cognitive deficits are reported in these patients before any definitive treatment, at 3 months postraadiotherapy, and even at 5 years of follow-up. Cognitive decline in some domains among patients receiving radiation therapy was reported by Prabhu et al. in 2014 at 1, 2, 3, and 5 years. However, Arreguin Gonzalez et al. reported in a case report that cognitive functions such as attention, language, memory, praxis, thought, calculation, and executive function which were impaired before surgery were improved 3 months after surgery, but not after 1 week of surgery. Cognitive improvements at 3 months postoperatively are also reported by Koizumi et al. in 2014 in patients suffering from meningioma and have associated it with recovered neuronal viability as evidenced by single-photon emission computed tomography. In this study, at 1 month follow-up after the surgery, the cognitive function remained same without much improvement. However, there was a significant improvement in recognition, and mild improvement was shown in domains of recent memory, and verbal retention to dissimilar pairs. Even 1 month could be too early for regaining the cognitive function which was disturbed due to the paraneoplastic or treatment effect.

The overall cognitive function at 6 months following surgery was significantly improved (P = 0.008). Though there was an improvement of cognitive function in all domains at 6 months, mental balance, verbal retention of dissimilar pairs and recognition have shown significant improvement [Table 3]. There was a consistent
improvement in all these 3 domains from the baseline to 1 month and then to 6 months. Even though the overall cognitive function was significantly improved at 6 months, dysfunction persisted in few of the cognitive domain such as recent memory, verbal retention, and visual retention. The improvement in cognitive status following surgery is likely due to improved perfusion in the adjacent areas.\(^7\)

The cognitive deficits identified in this study before initiation of radiotherapy, chemotherapy, or surgery explains the influence of tumor and its pathological process on cognitive deficits. It is reported that patients with frontal glioma exhibit more cognitive deficits due to the damage in the frontal lobe.\(^2\) Even though the influence of tumor location on cognitive dysfunction was not analyzed in this study, it remained inferior in patients with axial tumors as compared to patients with extra-axial tumors.

Cognitive function was found to be better in patients with benign tumor and poor in patients who underwent radiotherapy at all points of assessment. The majority of the patients who received radiotherapy had a malignant tumor. The aggressive nature of the tumor along with radiotherapy can result in higher cognitive dysfunction. A mild deterioration in cognitive function at 1 month observed in patients of the malignant tumor could be due to the transient neurotoxic effect of radiation.\(^3\)\(^,\)\(^4\) There could be the negative impact of radiation-induced inflammation on hippocampal neurogenesis as shown in animal models.\(^5\) Even though reduced brain volume in patients who are undergoing cranial irradiation is reported by many authors, Horská et al. in 2010 reported that the reduced vermis volume was not responsible for cognitive deficits and highlighted the importance of considering the influence of brain malignancy and preradiation treatment on cognitive deficits.\(^5\) Radiation therapy also produces leukoencephalopathy, radiation necrosis, and dementia.\(^5\) Armstrong et al. in 2002 have reported reduced toxic effects with current radiation therapy techniques.\(^1\) Increased severity of cognitive dysfunction is reported in patients who received radiotherapy along with chemotherapy.\(^6\),\(^7\) It is reported having cognitive dysfunction like memory loss, decreased information processing speed, and reduced attention in patients who received chemotherapy for a brain tumor.\(^2\) Though the influence of chemotherapy on cognitive dysfunction is not studied much, Flissbach et al. in 2005 reported that methotrexate-based chemotherapy did not produce gross cognitive deficits in patients with lymphoma at 1 year of follow-up.\(^3\) However, he observed that cognitive deficits were retained when patients had a residual tumor.

Cognitive dysfunction leads to difficulties in performing cognitive tasks, contribute to functional disability, and behavioral changes and thus, makes the individual handicapped.\(^9\) Patient’s ability to perform ADL is directly related to the cognitive function.\(^9\) Caregivers of patients with cognitive deficits are reported providing more assistance with ADL than those without cognitive deficits.\(^28\) Cognitive deficits in these patients are a good predictor of poor QoL not only in patients,\(^13\) but also in family caregivers.

This study is limited because of small sample size. Multicenter studies of larger sample size are needed to identify the significant relationship of various factors described in this study. A long-term follow-up of cognitive function will aid in cognitive rehabilitation which can be individualized for the patients with and without improvement in the cognitive function. As the cognitive dysfunction was found persisting even at 6 months, monitoring cognitive task, and developing appropriate management strategies are important to equip these patients in their personal, as well as social life. The neuro-oncology team must facilitate this to improve QoL for patients and their caregivers. Socioeconomic barriers are reported to result in irregular follow-up visits and poor outcome among neurosurgical patients.\(^9\) Guiding the patients and caregivers to overcome such barriers could also improve the rate of follow-up. Present findings can aid in exploring more about cognitive aspect of these patients.

**CONCLUSION**

Patients with intracranial tumors have substantial cognitive dysfunction before any definite treatment. However, there was a significant improvement in cognitive function at 6 months following surgery with deficits persisting in some domains. One of the long-term goals for the neuro-oncology team must be to reduce the cognitive sequelae of these tumors with improvement in treatment modalities.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. Armstrong CL, Hunter JV, Ledakis GE, Cohen B, Tallent EM, Goldstein BH, et al. Late cognitive and radiographic changes related to radiotherapy: Initial prospective findings. Neurology 2002;59:40-8.

2. Arreguin González IJ, Galicia RD, Yáñez G, Edgardo R, Luviano VL, Hernández L. Neuropsychologic evaluation in a patient with a frontal meningioma. Arch Neuropsychiatria Clin 2008;13:59-68.

3. Bunevicius A, Tamasauskas S, Deltuva V, Tamasauskas A, Radziunas A, Bunevicius R. Predictors of health-related quality of life in neurosurgical brain tumor patients: Focus on patient-centered perspective. Acta Neurochir (Wien) 2014;156:367-74.

4. Correa DD, Shi W, Thaler HT, Cheung AM, DeAngelis LM, Abrey LE.
Longitudinal cognitive follow-up in low-grade gliomas. J Neurooncol 2008;86:321-7.

5. Dhandapani M, Gupta S, Dhandapani S, Kaur P, Samra K, Sharma K, et al. Study of factors determining caregiver burden among primary caregivers of patients with intracranial tumors. Surg Neurol Int 2015;6:160.

6. Dhandapani S, Karthigeyan M, Dhandapani M. Unusual presentation of hypophagia after surgery for fourth ventricular ependymoma: Accessory satiety center or hypothalamic seedlings? Neurol India 2013;61:320-1.

7. Dhandapani S, Sharma A, Sharma K, Das L. Comparative evaluation of MRS and SPECT in prognostication of patients with mild to moderate head injury. J Clin Neurosci 2014;21:745-50.

8. Dhandapani S, Sharma K. Is “en-bloc” excision, an option for select large vascular meningiomas? Surg Neurol Int 2013;4:102.

9. Dhandapani SS, Manju D, Mahapatra AK. The economic divide in outcome following severe head injury. Asian J Neurosurg 2012;7:17-20.

10. Dwarka P, Santosh KV. Handbook of PGI Battery of Brain Dysfunction (PGI-BBD) Agra: National Psychological Corporation, Modern Printers; 1990. p. 172.

11. Ellenberg L, Liu Q, Gioia G, Yasui Y, Packer RJ, Mertens A, et al. Neurocognitive status in long-term survivors of childhood CNS malignancies: A report from the childhood cancer survivor study. Neuropsychology 2009;23:705-17.

12. Filey CM, Kleinschmidt-DeMasters BK. Neurobehavioral presentations of brain neoplasms. West J Med 1995;163:19-25.

13. Fliesbach K, Helmsaeter C, Urbach H, Althaus A, Pels H, Linnebank M, et al. Neuropsychological outcome after chemotherapy for primary CNS lymphoma: A prospective study. Neurology 2005;64:1184-8.

14. Gehrke AK, Baisley MC, Sonck AL, Wronski SL, Feuerstein M. Neurocognitive deficits following primary brain tumor treatment: Systematic review of a decade of comparative studies. J Neurooncol 2013;115:135-42.

15. Horská A, Laclair A, Mohamed M, Wells CT, McNutt T, Cohen KJ, et al. Cognitive and psychological disorders of caregiving: A detailed comparison between dementia and nondementia caregivers. Gerontologist 1999;39:177-85.

16. Horska A, Laclair A, Mohamed M, Wells CT, McNutt T, Cohen KJ, et al. Low cerebellar vermis volumes and impaired neuropsychologic performance in children treated for brain tumors and leukemia. AJNR Am J Neuroradiol 2010;31:1430-7.

17. Howlader N, Noone AM, Krapcho M, Garshall J, Miller D, Altekruse SF, et al. editors. SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD. Based on November 2013 SEER Data Submission. Posted to the SEER Web Site; April, 2014. Available from: http://www.seer.cancer.gov/csr/1975_2011/.[Last accessed on 2015 Jul 08].

18. Kangas M, Tate RL, Williams JR, Snee RJ. The effects of radiotherapy on psychosocial and cognitive functioning in adults with a primary brain tumor: A prospective evaluation. Neuro Oncol 2012;14:1485-502.

19. Koizumi H, Ideguchi M, Iwanaga H, Shirao S, Sadahiro H, Oka F, et al. Cognitive dysfunction might be improved in association with recovered neuronal viability after intracranial meningioma resection. Brain Res 2014;1574:50-9.

20. Lagier CN, Cerhan JH, Locke DE, Anderson SK, Wu W, Brown PD. Comparing neuropsychological tasks to optimize brief cognitive batteries for brain tumor clinical trials. J Neurooncol 2010;96:271-6.

21. Liu R, Page M, Solheim K, Fox S, Chang SM. Quality of life in adults with brain tumors: Current knowledge and future directions. Neuro Oncol 2009;11:330-9.

22. Marsh JC, Gielda BT, Herskovic AM, Abrams RA. Cognitive sparing during the administration of whole brain radiotherapy and prophylactic cranial irradiation: Current concepts and approaches. J Oncol 2010;2010:198208.

23. Martens T, Rotermund R, Zu Eulenburg C, Westphal M, Fritsch J. Long-term follow-up and quality of life in patients with intracranial germinoma. Neurosurg Rev 2014;37:445-50.

24. Meyers CA, Weitzner MA, Valentine AD, Levin MA. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol 1998;16:2522-7.

25. Mu YG, Huang LJ, Li SY, Ke C, Chen Y, Jin Y, et al. Working memory and the identification of facial expression in patients with left frontal glioma. Neuro Oncol 2012;14 Suppl 4:v81-9.

26. Mulhern RK, Merchant TE, Gajjar A, Reddick WE, Kun LE. Late neurocognitive sequelae in survivors of brain tumours in childhood. Lancet Oncol 2004;5:399-408.

27. Neisser U. Cognitive Psychology. Englewood Cliffs: Prentice-Hall; 1967.

28. Ory MG, Hoffman RR 3°, Yee JL, Tennstedt S, Schulz R. Prevalence and impact of caregiving: A detailed comparison between dementia and nondementia caregivers. Gerontologist 1999;39:177-85.

29. Palmer SL, Goloubeva O, Reddick WE, Glass JO, Gajjar A, Kun L, et al. Patterns of intellectual development among survivors of pediatric medulloblastoma: A longitudinal analysis. J Clin Oncol 2001;19:2302-8.

30. Poggi G, Liscio M, Galbiati S, Adduci A, Massimino M, Gandola L, et al. Brain tumors in children and adolescents: Cognitive and psychological disorders at different ages. Psychooncology 2005;14:386-95.

31. Prabhu RS, Won M, Shaw EG, Hu C, Brachman DG, Buckner JC, et al. Effect of the addition of chemotherapy to radiotherapy on cognitive function in patients with low-grade glioma: Secondary analysis of RTOG 98-02. J Clin Oncol 2014;32:535-41.

32. Satoer D, Vork J, Visch-Brink E, Snits M, Dirven C, Vincent A. Cognitive functioning early after surgery of gliomas in eloquent areas. J Neurosurg 2012;117:831-8.

33. Schindler MK, Forbes ME, Robbins ME, Riddle DR. Aging-dependent changes in the radiation response of the adult rat brain. Int J Radiat Oncol Biol Phys 2008;70:826-34.

34. Sherwood PR, Given BA, Doorenbos AZ, Given CW. Forgotten voices: Lessons from bereaved caregivers of persons with a brain tumour. Int J Palliat Nurs 2004;10:67-75.

35. Surma-aho O, Niemelä M, Vilikki J, Kouri M, Brander A, Salonen O, et al. Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients. Neurology 2001;56:1285-90.

36. Taylor BV, Buckner JC, Cascino TL, O’Fallon JR, Schaefer PL, Dinapoli RP, et al. Effects of radiation and chemotherapy on cognitive function in patients with high-grade gliomas. J Clin Oncol 1998;16:2195-201.

37. van der Vossen S, Schepers VP, Berkelbach van der Sprenkel JW, van der Schans CM, Chute CG. Cognitive and neuropsychological sequelae in survivors of brain tumors in children and adolescents: A longitudinal analysis. J Neurooncol 2008;86:321-7.

38. Welzel G, Steinvorth S, Wenz F. Cognitive effects of chemotherapy and/or radiotherapy on cognitive functioning in patients with brain tumors: Current knowledge and future directions. Neuro Oncol 2013;15(Suppl 4):iv81-9.

39. Working group on behalf of the International Pediatric Oncology Society. New and emerging topics in the childhood cancer survivor study. Neuropsychology 2009;23:705-17.

40. Zhu C, Bartolo M, Di Lorenzo C, Villani V, Pace A. Cognitive impairment in primary brain tumors outpatients: A prospective cross-sectional survey. J Neurooncol 2013;112:455-60.